-

Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023. Giovanni Caforio, M.D., board chair and chief executive officer, and Chris Boerner, Ph.D., executive vice president and chief operating officer, will answer questions about the company during a fireside chat at 8 a.m. EDT.

Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following the session’s conclusion.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Release Versions
$Cashtags

More News From Bristol Myers Squibb

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma...

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis...

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend...
Back to Newsroom